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Abstract
Visit-to-visit blood pressure variability has received considerable attention recently. The objective
of our study is to define a variability measure that is independent of change over time and
determine the association between longitudinal summary measures of blood pressure
measurements and mortality risk. Data for the study came from a prospective cohort of 2,906
adults, age 60 or older, in an urban primary care system with up to fifteen years follow-up. Dates
of death for deceased participants were retrieved from the National Death Index. Systolic and
diastolic blood pressure measurements from outpatient clinic visits were extracted from the
Regenstrief Medical Record System. For each patient, the intercept, regression slope, and root
mean square error for visit-to-visit variability were derived using linear regression models and
used as independent variables in Cox's proportional hazards models for both all-cause mortality
and mortality due to coronary heart disease or stroke. Rate of change was associated with
mortality risk in a U-shaped relationship and that participants with little or no change in blood
pressure had the lowest mortality risk. Blood pressure variability was not an independent predictor
of mortality risk. By separating change over time from visit-to-visit variability in studies with
relatively long follow-up, we demonstrated in this elderly primary care patient population that
blood pressure changes over time, not variability, were associated with greater mortality risk.
Future research is needed to confirm our findings in other populations.
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Introduction
Visit-to-visit blood pressure (BP) variability has received considerable attention recently.
Some studies reported that increased visit-to-visit blood pressure was associated with higher
risk of cardiovascular diseases (CVD) 1-4 and all-cause mortality. 5-7 There were also
suggestions that visit-to-visit BP variability should be used as a potential target for drug
development and treatment management.8 However, results on the relationship between BP
variability and health outcomes have not been entirely consistent, as other studies failed to
detect significant associations between BP variability and cardiovascular endpoints 9-11 or
found a weaker effect of BP variability than mean BP.12
Many studies had defined BP variability as the standard deviation of repeated BP
measurements from each subject. While such a definition may be a valid measure of
variability over a short period when there is little BP change, in studies conducted over
longer periods BP standard deviation would reflect both temporal trend in BP and visit-to-
visit variability. Thus, individuals with large standard deviation could have increasing or
decreasing BP over time but with little deviation from such a trend, or alternatively, they
could show little change over time but have large fluctuations in BP across time. A
schematic illustration was provided in Figure 1 where two individuals with similar BP mean
and standard deviations demonstrated different trends in BP change and variability over
time. Using the standard deviation to define visit-to-visit BP variability is therefore
incapable of distinguishing change over time from true visit-to-visit variability. A redefined
BP variability will be particularly relevant to the elderly population who were known to
have decreasing diastolic BP after age 60 and continual rise in systolic BP over time.13 To
the best of our knowledge, only one study thus far has considered a definition of BP
variability that is independent of BP temporal trends in postmenopausal women for stroke
risk. 4
In this study, we present results from a longitudinal study of elderly primary care patients
enrolled in an urban health care system by capturing three quantitative measures (mean,
slope and variability) associated with longitudinal BP measurements and determine their
combined association with mortality.
Methods
Study Population
The cohort consisted of elderly primary care patients who were enrolled during regularly
scheduled primary care appointments in an urban public health system. From 1991 to 1993,
all patients 60 years and older attending the primary care practice in the Wishard Health
System were approached for participating in a depression screening study. A total of 4,413
primary care patients were contacted, of whom 115 patients refused; 57 were not able to
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complete the testing due to severe cognitive impairment; and 284 patients were not eligible
because they did not speak English, were in prison or a nursing home, or had a hearing
impairment, leaving 3,957 total enrolled patients. The details of the depression screening
program have been previously reported.14,15 To ensure comparability with previous studies,1
we restricted the analyses to patients who were followed for at least two years and had at
least six BP measurements. Therefore, 2906 patients were included in this analysis. The
study was approved by the Institutional Review Boards of Indiana University-Purdue
University of Indianapolis.
Data Source during Patient Follow-up
Medical history information from enrollment to December 31, 2006 was extracted from the
Regenstrief Medical Record System.16 At all of the sites of care in the targeted health
system, providers electronically recorded BP measurements, height, weight, all diagnoses,
laboratory test results, procedures, and prescribed medications. This information was
routinely collected and stored in the Regenstrief Medical Record System that had been used
extensively for epidemiologic studies of the process and outcomes of care.17 For this
analysis, we retrieved repeated height, weight, systolic BP (SBP) and diastolic BP (DBP)
from patients’ pre-scheduled outpatient visits. We also retrieved dates for patients’ first
diagnoses (as indicated by ICD-9 codes) contained in inpatient, outpatient and emergency
room records for the following conditions: hypertension, diabetes, atherosclerotic vascular
disease, coronary artery disease (CAD), peripheral artery disease (PAD), congestive heart
failure (CHF), cerebrovascular disease (CVD), cancer, anemia, chronic obstructive
pulmonary disease (COPD), arthritis, liver disease, renal disease, thyroid disease (including
both hyperthyroidism and hypothyroidism), hyperlipidemia, dementia, and depression.
Demographic information including age, gender, race, years of education, and history of
smoking were collected at study enrollment.
Study Endpoint
For deceased patients, date of death from enrollment to December 31, 2006 was retrieved
from the National Death Index (NDI) as part of the National Center for Health Statistics.
The NDI is a central computerized index of death record information on file in the state vital
statistics offices.18 For surviving patients, date of their last outpatient clinic visit before Dec.
31, 2006 was used as the censoring date. In addition to examining all-cause mortality, we
also determined deaths for which ischemic coronary heart disease (CHD) (International
Classification of Diseases, Ninth Revision, codes 410–414 and International Classification
of Diseases, Tenth Revision, codes I20–I25), or for which stroke (International
Classification of Diseases, Ninth Revision, codes 430-434 and International Classification of
Diseases, Tenth Revision, codes I60-I69) was listed as the cause of death.
Statistical Analysis
For each patient, three independent BP summary measures were calculated using linear
regression models, with BP measurements as dependent variables and the time of BP
measurement as the independent variable with baseline time as the time origin: (1) the
intercept, which represents BP value at baseline, (2) the regression slope, which estimates
the rate of BP change per year during follow-up, and (3) root mean square error, which
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estimates BP variability around the fitted linear regression line. The three summary BP
measures were calculated separately for SBP and DBP.
Cox's proportional hazards models were used to determine whether the three BP
characteristic measures, alone or in combinations, were associated with all-cause or
cardiovascular mortality risk. BP intercepts, slopes, and variability were included in the
Cox's models first as continuous variables to detect both linear and quadratic effects on
mortality risk. For each of the three BP measures, we also used quartile groups in order to
detect potential non-linear effects in mortality risk. All medical conditions were used as
time-varying covariates in the proportional hazard models and included in the multivariate
models for conditions with p<0.05. To prevent bias due to reverse causation from decreasing
BP prior to death, we also conducted a sensitivity analysis by excluding BP measurements
taken within one year of study endpoints.
Comparisons between patients included in this analysis and those excluded were conducted
using t-tests for continuous outcomes and chi-squared tests for categorical outcomes.
Results
Among 2906 patients included in this analysis, 1711 (59%) died during follow-up, 305 of
the deaths had coronary heart disease listed as the cause of death and 123 had stroke as
cause of death. Median follow-up time from enrollment to study endpoint was 12.9 years
with survival time in the range of 2.0 year to 16.0 years. In Table 1, we included
comparisons of baseline demographic information and medical history for patients who died
during follow-up and those who survived to Dec. 31, 2006. We also included mean BP
intercept, slope, and variability measures for the two groups. BP intercepts did not differ
between the deceased and surviving patients, but deceased patients had significantly smaller
slopes indicating greater BP decline than patients who survived to Dec. 31, 2006. Mean BP
variability was not significantly different on SBP. However, deceased patients had
significantly smaller variability than survivors did on DBP (p=0.002).
In table 2, we included results from multivariate Cox's models for all-cause mortality using
each of the three quantitative BP measures as both continuous or quartile groups adjusting
for age, gender, race, smoking status and body mass index (BMI). The models indicated that
BP intercepts (baseline BP) were not associated with mortality risk. A U-shaped relationship
were seen between BP slopes and all-cause mortality indicating that patients with both large
(1st quartile group) and small BP changes (4th quartile group) over the follow-up time had
higher mortality risk compared to patients with little changes in BP (3rd quartile group) over
time. When both SBP slopes and variability were included in the Cox's model, SBP
variability was not associated with mortality (p=0.32). Those with smaller DBP variability
(1st quartile group) was associated with greater mortality risk compared to those in the 4th
quartile group (HR=1.355, p<0.001). Model results for CHD or stroke mortality were
included in Table 3. BP variability was not a predictor of cardiovascular deaths, but higher
SBP intercept was significantly associated with higher stroke mortality (p=0.0297).
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Slope and variability measures were significantly correlated for DBP (r=0.107, p<0.001) but
not for SBP (r=0.026, p=0.16). To investigate potential interactions among slope and
variability measures with a reasonable number of groups, we combined the 2nd and 3rd slope
quartile groups into one group and combined the 2nd, 3rd and 4th variability quartile groups
into one group since these groups showed similar trends in Table 2. Thus, patients were
divided into six groups according to their combined BP slope and variability measures
(Supplemental Table). Results from Cox's models for all-cause mortality using the combined
six BP slope and variability groups were presented in Table 4. For SBP, patients who had
little or no change over time regardless of variability had the smallest mortality risk out of
the six groups. In patients with declining BP or little change in BP (the small or medium
slope groups), smaller SBP variability was associated with significantly higher all-cause
mortality compared to those with medium to large variability. Similar results were also seen
for DBP variability. A sensitivity analysis excluding BP measurements obtained within 1
year of study end points was also included in Table 4 and results were similar to those
obtained using the entire follow-up data.
Results from multivariate Cox's model on cause specific mortality due to CHD or stroke
were presented in Table 5. Similarly to what we had seen for all-cause mortality, patients
with little change in SBP over time (groups 3 and 4) were again found to have the lowest
mortality risk for both CHD and stroke. Given similar BP change over time, no significant
differences in cause-specific mortality risk were found between patients with small
variability and those with medium to large variability (p>0.05). However, in contrast to
results for all-cause mortality, patients in group 1 generally did not show increased risk for
cardiovascular death with the exception of DBP for CHD deaths where those in group still
showed an increased risk (HR=1.761, p=0.0130).
Comparisons between participants in the cohort who were excluded from the analysis
(n=1051) to those included (n=2906) showed that those included in the analyses were
slightly younger (mean age=67.5 vs 69.1, p<0.001), with higher BMI at baseline (mean
BMI=29.8 vs 26.9, p<0.001), with higher proportions of female (72.3% vs 59.1%, p<0.001)
and African Americans (65.9% vs 56.2%, p<0.001). However, there was no significant
difference between years of education or smoking history between those included and those
excluded from the analyses.
Discussion
In this elderly primary care patient cohort followed for up to 15 years, we found that
participants with little BP change over time had the lowest risk for all-cause mortality or
cardiovascular deaths. BP variability was not an independent predictor of mortality risk.
Previous studies, with two exceptions,4,7 used within-person standard deviation for BP
variability that measures BP deviations about the mean. A recent study defined BP
variability as the average absolute difference between successive BP measurements that also
includes trends of change. 7 Higher within-person standard deviation may be accounted for
by BP change over time, not simply visit-to-visit variation. Thus, previous reports of
increased CVD and mortality risk with higher BP standard deviation could be due to BP
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change over time. In contrast, the BP variability defined in our study measures BP
deviations about a fitted regression line. Our results demonstrate that BP change over time
was significantly associated with mortality risk while the redefined visit-to-visit variability
is not a predictor of mortality. In addition, we note that studies using standard deviation as a
variability measure within a short period tend to report non-significant relationship between
such measures and cardiovascular diseases, perhaps due to the relatively stable BP change
within the short time window. 9,10,19 In studies with BP measured over an extended period,
our definition of variability should be preferred, as it separates BP change over time from
random variability. It will be interesting to re-evaluate previous studies to determine how
much of the reported association between increased variability and disease risks was
accounted for by BP changes over time.
There is only one previous study that adopted BP variability similarly defined as in this
study.4 The study population included postmenopausal women aged 50 to 79 years from the
Women's Health Initiatives (WHI) for the risk of stroke. However, the WHI study found that
larger BP variability was related to higher stroke risk, in contrast to our findings. There is
important cohort and methodological differences between our study and the WHI study,
however. Our cohort included both men and women who were on average older than WHI
participants. Our outcome was mortality, where WHI considered stroke risk. In addition, in
our analyses, we considered nonlinear temporal trend to accommodate a U-shaped
relationship between BP change and mortality risk, where the WHI study used linear models
for BP slopes. These differences and potentially others not postulated here may have
contributed to the differences in findings.
Our finding that elderly participants with little or no change in BP had the lowest mortality
risk is not surprising. A J- or U-shaped relationship between BP, coronary artery disease and
mortality have been reported, where both low and high BP were shown to have increased
risk. 20-22 Our results support a nonlinear relationship between BP slopes and all-cause or
cardiovascular mortality risk and that participants with both increasing or decreasing BP had
higher mortality risk than those with little change in BP over time. Furthermore, the
relationship between BP change and mortality was independent of BP variability.
Our finding that given similar diastolic BP change over time, participants with smaller
variability had higher all-cause mortality than those with medium to large variability has not
been reported before. However, we did not find significant relationship between diastolic BP
variability and cause-specific mortality due to CHD or stroke. A plausible mechanism
underlying a relationship between smaller BP variability and higher all-cause-mortality is
not clear. It is possible that larger BP variability reflects an intact or healthier cardiovascular
system to accommodate BP increases when one exercises, for example. Although not
directly correlated with BP, reduced heart rate variability had been shown to be a risk factor
for cardiac events.23,24 Additional research is necessary to investigate potential mechanisms
linking small BP variability to increased all-cause mortality risk.
Our study has a number of strength. The cohort is relatively large with long follow-up
period. The use of electronic medical records (EMR) and National Death Index data
eliminates recall and potential attrition bias. A comprehensive list of medical conditions was
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available from EMR so that relevant covariates can be included in the analysis. Our study
also has important limitations. The first is that BP was obtained as part of clinical practice
records, not as a part of research study. Nevertheless, these data were routinely used to
support clinical care and in many research projects. The second limitation is that some
participants may be experiencing medical events that could adversely affect BP measures
taken during that time. However, we have excluded BP taken during emergency room visits
or hospital stay by restricting BP measurements to those from pre-scheduled outpatient visits
in order to minimize potential contamination bias. We also conducted a sensitivity analysis
by excluding BP measured within one year of study endpoints to minimize the potential for
reverse causation. Lastly, additional data such as frailty measures on patients in this cohort
were not collected in the EMR and they may provide some insight for the higher all-cause
mortality risk in patients in group one who experience steep BP decline with small
variability.
Perspectives
In this study, we defined visit-to-visit blood pressure variability as a measure independent of
blood pressure change over time. In an elderly primary care patient cohort followed over
fifteen years, we found that participants with little BP change over time had the lowest all-
cause and cardiovascular mortality risk. BP variability was not an independent predictor of
mortality risk. Future research is needed to adopt this new measure and confirm our findings
in other populations.
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Novelty and Significance
What is New?
• Visit-to-visit blood pressure variability is defined as a measure independent of
change over time;
• The re-defined blood pressure variability is not associated with all-cause
mortality or cardiovascular deaths in this elderly primary care patient cohort;
• Rate of blood pressure change is associated with mortality risk in a U-shaped
relationship. Participants with little or no change in BP had the lowest risk for
all-cause or cardiovascular mortality.
What is Relevant?
• In elderly patients with repeated blood pressure measurements, it is important to
monitor patients’ blood pressure change over time for better health outcomes.
Summary:
Elderly participants with stable blood pressure over time had the lowest mortality risk.
Blood pressure variability was not an independent predictor of mortality risk. Participants
with little or no change in blood pressure had the lowest all-cause or cardiovascular
mortality risk. Future research is needed to adopt this new measure and confirm our
findings in other populations.
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Figure 1.
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Schematic illustration of two groups of individuals with similar mean and standard deviation
of blood pressure measurements over 13 years, but showing different change over time.
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Table 1
Participants’ demographic characteristics at baseline and within-subject blood pressure summary measures by
mortality status.
Patients’ Characteristic Mortality Status
Survivors (n =1195) Deceased (n =1711) p value
Mean age, (SD) 66 (6.2) 69.4 (7.9) <.0001
Female, n (%) 1166 (78.7) 1555 (62.9) <.0001
Black, n (%) 991 (66.9) 1515 (61.2) 0.0004
Smoking, n (%) 350 (23.6) 838 (33.9) <.0001
Mean years of education, (SD) 9.3 (3.1) 8.7 (3.2) <.0001
Body mass index, kg/m2 (SD) 30.3 (7.2) 28.3 (7.4) <.0001
Body mass index groups, n (%):
    Underweight 46 (3.1) 176 (7.1) <.0001
    Normal weight 305 (20.6) 718 (29.0)
    Overweight 435 (29.4) 733 (29.6)
    Obese 696 (47.0) 848 (34.3)
Anemia, n (%) 215 (14.5) 519 (21.0) <.0001
Arthritis, n (%) 454 (30.6) 710 (28.7) 0.1932
Atherosclerotic vascular disease, n (%) 12 (0.8) 58 (2.3) 0.0004
Coronary artery disease, n (%) 252 (17.0) 602 (24.3) <.0001
Cancer, n (%) 148 (10.0) 376 (15.2) <.0001
Cerebrovascular disease, n (%) 98 (6.6) 331 (13.4) <.0001
Congestive heart failure, n (%) 144 (9.7) 521 (21.1) <.0001
COPD, n (%) 119 (8.0) 532 (21.5) <.0001
Dementia, n (%) 36 (2.4) 76 (3.1) 0.2389
Depression, n (%) 137 (11.5) 219 (12.8) 0.2801
Diabetes, n (%) 287 (19.4) 725 (29.3) <.0001
Hyperlipidemia, n (%) 294 (24.6) 405 (23.7) 0.5629
Hypertension, n (%) 1046 (70.6) 1760 (71.1) 0.7220
Liver disease, n (%) 50 (3.4) 109 (4.4) 0.1102
Renal disease, n (%) 5 (0.3) 17 (0.7) 0.1524
Taking antihypertensive medications, n (%) 1111 (93.0) 1496 (87.8) <0.001
Systolic blood pressure
    Mean intercept, mmHg (SD) 142.1 (15.4) 142.5 (16.6) 0.5159
    Mean slope, mmHg/year (SD) 0.5 (2.8) −0.0 (4.7) 0.0007
    Mean variability, mmHg (SD) 17.6 (4.7) 17.5 (4.8) 0.7071
Diastolic blood pressure
    Mean intercept, mmHg (SD) 80.1 (8.5) 80.1 (9.1) 0.9292
    Mean slope, mmHg/year (SD) −0.9 (1.6) −1.6 (2.6) <.0001
    Mean variability, mmHg (SD) 10.9 (2.7) 10.6 (3.0) 0.0017
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Table 2
Results from multivariate Cox's proportional hazard models for all-cause mortality using baseline blood
pressure, changes in blood pressure over time (slope estimates) or blood pressure variability.*
BP Characteristic Systolic Blood Pressure Diastolic Blood Pressure
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Continuous Models
        BP Intercept 1.002 (0.999, 1.005) 0.2901 1.005 (0.999, 1.010) 0.0855
        BP Slope 0.954 (0.944, 0.965) <.0001 0.933 (0.907, 0.960) <.0001
        BP Slope2 1.004 (1.003, 1.005) <.0001 1.012 (1.008, 1.015) <.0001
        BP Variability 0.994 (0.984, 1.004) 0.2563 0.970 (0.953, 0.987) 0.0005
        BP Slope 0.954 (0.944, 0.965) <.0001 0.936 (0.910, 0.963) <.0001
        BP Slope2 1.004 (1.003, 1.005) <.0001 1.012 (1.008, 1.015) <.0001
        BP Variability 0.995 (0.985, 1.005) 0.3223 0.979 (0.963, 0.997) 0.0186
Categorical Models
    Baseline quartile groups 0.6395 0.1197
    Slope quartile groups <.0001 <.0001
        1st quartile 1.332 (1.177, 1.507) <.0001 2.047 (1.800, 2.328) <.0001
        2nd quartile 0.607 (0.528, 0.697) <.0001 0.995 (0.867, 1.141) 0.9372
        3rd quartile 0.608 (0.529, 0.699) <.0001 0.713 (0.615, 0.826) <.0001
        4th quartile 1 Reference 1 Reference
    Variability quartile groups 0.3098 <.0001
        1st quartile 1.091 (0.953, 1.249) 0.2089 1.355 (1.184, 1.552) <.0001
        2nd quartile 0.963 (0.841, 1.104) 0.5918 1.022 (0.890, 1.174) 0.7541
        3rd quartile 0.994 (0.870, 1.136) 0.9291 1.060 (0.923, 1.217) 0.4078
        4th quartile 1 Reference 1 Reference
*
models adjusted for baseline age, gender, race, smoking status, and body mass index.
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Table 3
Results from multivariate Cox's proportional hazard models for mortality due to coronary heart disease or
stroke using baseline blood pressure, changes in blood pressure over time (slope estimates) or blood pressure
variability.*
BP Characteristic Systolic Blood Pressure Diastolic Blood Pressure
Hazard Ratio (95% CI) P-value Hazard Ratio (95% CI) P-value
Coronary Heart Disease
    BP Intercept 1.007 (1.000, 1.015) 0.0516 1.013 (0.999, 1.026) 0.0624
    BP Slope 0.962 (0.935, 0.991) 0.0098 1.897 (0.829, 0.971) 0.0071
    BP Slope2 1.003 (1.002, 1.005) <0.0001 1.008 (0.999, 1.017) 0.0939
    BP Variability 1.019 (0.995, 1.044) 0.1147 1.009 (0.969, 1.051) 0.6537
    BP Slope 0.963 (0.935, 0.992) 0.0114 0.893 (0.824, 0.968) 0.0061
    BP Slope2 1.003 (1.002, 1.005) <0.0001 1.008 (0.998, 1.017) 0.1051
    BP Variability 1.020 (0.995, 1.044) 0.1131 1.021 (0.981, 1.063) 0.3069
Stroke
    BP Intercept 1.011 (1.000, 1.023) 0.0497 1.014 (0.994, 1.036) 0.1774
    BP Slope 1.052 (0.988, 1.120) 0.1119 1.063 (0.987, 1.144) 0.1081
    BP Slope2 1.002 (0.999, 1.005) 0.2747 1.017 (1.007, 1.026) 0.0007
    BP Variability 1.057 (1.020, 1.096) 0.0022 1.035 (0.972, 1.102) 0.2802
    BP Intercept 1.016 (1.002, 1.031) 0.0297 --
    BP Slope 1.106 (1.052, 1.163) <0.0001 1.060 (0.984, 1.142) 0.1273
    BP Slope2 -- 1.017 (1.007, 1.027) 0.0007
    BP Variability 1.035 (0.993, 1.079) 0.1081 1.034 (0.972, 1.100) 0.2945
*
models adjusted for baseline age, gender, race, smoking status, and body mass index.
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Table 4
Multivariate Cox's proportional hazard models assessing the association between longitudinal blood pressure
characteristics and risk of all-cause mortality.*
Patient Groups Systolic BP Diastolic BP
Hazard Ratio (95%
Confidence Interval)
P-value Hazard Ratio (95%
Confidence Interval)
P-value
Entire Sample
    Group 1 (small slopes, small variability) 1.672 (1.373, 2.037)
<.0001‡ 2.156 (1.788, 2.599) <.0001
    Group 2 (small slopes, medium to large variability) 0.951 (0.824, 1.098) 0.4910 1.952 (1.673, 2.278) <.0001
    Group 3 (medium slopes, small variability) 0.692 (0.578, 0.828)
<.0001‡ 1.332 (1.107, 1.601) 0.0024‡
    Group 4 (medium slopes, medium to large
variability)
0.542 (0.473, 0.621) <.0001 0.771 (0.669, 0.888) 0.0003
    Group 5 (large slopes, small variability) 0.997 (0.799, 1.243) 0.9773 1.573 (1.252, 1.976)
<.0001‡
    Group 6 (large slopes, medium to large variability) 1 Reference 1 Reference
Sensitivity Analysis†
    Group 1 (small slopes, small variability) 1.556 (1.283, 1.889)
<.0001‡ 2.298 (1.909, 2.766) <.0001‡
    Group 2 (small slopes, medium to large variability) 0.749 (0.648, 0.865) <.0001 1.725 (1.477, 2.015) <.0001
    Group 3 (medium slopes, small variability) 0.595 (0.496, 0.713)
<.0001‡ 1.270 (1.051, 1.534) 0.0132‡
    Group 4 (medium slopes, medium to large
variability)
0.469 (0.410, 0.537) <.0001 0.657 (0.570, 0.757) <.0001
    Group 5 (large slopes, small variability) 1.804 (1.465, 2.221)
<.0001‡ 2.142 (1.736, 2.644) <.0001‡
    Group 6 (large slopes, medium to large variability) 1 Reference 1 Reference
*
models adjusted for age, gender, race, smoking status, body mass index, history of anemia, arthritis, atherosclerotic vascular disease,
cardiovascular disease, cancer, cerebrovascular disease, congestive heart failure, hyperlipidemia, hypertension, COPD, dementia, diabetes, liver
disease, renal disease and use of antihypertensive medications.
†Analysis excludes blood pressure measurements within one year of study end points.
‡p<0.05, significant difference in hazard ratios comparing the small variability group to the medium to large variability group within the same
slope groups.
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Table 5
Multivariate Cox's proportional hazard models assessing the association between longitudinal blood pressure
characteristics and mortality due to coronary heart disease or stroke.*
Patient Groups Systolic BP Diastolic BP
Hazard Ratio (95%
Confidence Interval)
P-value Hazard Ratio (95%
Confidence Interval)
P-value
Coronary heart disease
    Group 1 (small slopes, small variability) 1.176 (0.686, 2.017) 0.5554 1.761 (1.127, 2.754) 0.0130
    Group 2 (small slopes, medium to large variability) 1.371 (0.991, 1.896) 0.0567 2.307 (1.635, 3.254) <.0001
    Group 3 (medium slopes, small variability) 0.643 (0.420, 0.987) 0.0432 1.044 (0.671, 1.624) 0.8490
    Group 4 (medium slopes, medium to large variability) 0.471 (0.339, 0.654) <.0001 0.708 (0.510, 0.982) 0.0384
    Group 5 (large slopes, small variability) 1.116 (0.689, 1.808) 0.6549 1.046 (0.590, 1.855) 0.8765
    Group 6 (large slopes, medium to large variability) 1 Reference 1 Reference
Stroke
    Group 1 (small slopes, small variability) 0.797 (0.331, 1.915) 0.6113 0.739 (0.323, 1.686) 0.4718
    Group 2 (small slopes, medium to large variability) 0.655 (0.382, 1.124) 0.1244 1.028 (0.580, 1.821) 0.9259
    Group 3 (medium slopes, small variability) 0.361 (0.178, 0.735) 0.0050 0.510 (0.233, 1.115) 0.0915
    Group 4 (medium slopes, medium to large variability) 0.458 (0.291, 0.719) 0.0007 0.637 (0.406, 0.999) 0.0497
    Group 5 (large slopes, small variability) 0.630 (0.276, 1.438) 0.2726 1.149 (0.561, 2.354) 0.7044
    Group 6 (large slopes, medium to large variability) 1 Reference 1 Reference
Coronary heart disease or Stroke
    Group 1 (small slopes, small variability) 1.044 (0.660, 1.651) 0.8541 1.391 (0.944, 2.050) 0.0952
    Group 2 (small slopes, medium to large variability) 1.120 (0.851, 1.667) 0.4199 1.846 (1.381, 2.468) <.0001
    Group 3 (medium slopes, small variability) 0.545 (0.379, 0.785) 0.0011 0.854 (0.584, 1.249) 0.4148
    Group 4 (medium slopes, medium to large variability) 0.466 (0.357, 0.608) <.0001 0.680 (0.522, 0.886) 0.0043
    Group 5 (large slopes, small variability) 0.941 (0.622, 1.424) 0.7748 1.087 (0.695, 1.700) 0.7141
    Group 6 (large slopes, medium to large variability) 1 Reference 1 Reference
*Cause specific mortality models adjusted for age, gender, race, smoking status, history of anemia, arthritis, hyperlipidemia, COPD, dementia,
diabetes, and renal disease.
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